Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Recombinant G-CSF

Lenograstim

Brand names: Granocyte

Lenograstim is a recombinant granulocyte colony-stimulating factor (G-CSF) used to reduce the duration of neutropenia after chemotherapy or bone marrow transplantation and to mobilise peripheral blood stem cells.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a glycosylated recombinant human G-CSF that stimulates proliferation and differentiation of neutrophil progenitors and enhances the function and release of mature neutrophils.

Prescribing in practice

  • Splenic enlargement and rare splenic rupture can occur, so investigate left upper abdominal or shoulder-tip pain promptly.
  • It should not be given in the period immediately surrounding cytotoxic chemotherapy administration, in line with the SPC.
  • Bone pain is common and pulmonary adverse effects have been reported, warranting clinical vigilance.

Monitoring

Monitor full blood count regularly to guide therapy and detect excessive leucocytosis, and review for splenic and pulmonary adverse effects.

Counselling the patient

  • Bone or muscle aches are common and can usually be managed with simple analgesia.
  • Report severe pain in the upper left abdomen or tip of the shoulder promptly.
  • Attend for the blood tests needed to monitor your treatment.

Evidence & guidelines

Lenograstim use is supported by established evidence that G-CSF shortens the duration of chemotherapy-induced neutropenia and aids stem-cell mobilisation.

Reference: NICE; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways